Christopher Rovaldi M.Sc. Net Worth

The estimated Net Worth of Christopher Rovaldi is at least $863 Thousand dollars as of 6 April 2022. Mr Rovaldi owns over 1,728 units of Keros Therapeutics stock worth over $94,608 and over the last 7 years he sold KROS stock worth over $768,264.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Sc KROS stock SEC Form 4 insiders trading

Mr has made over 6 trades of the Keros Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 1,728 units of KROS stock worth $27,648 on 6 April 2022.

The largest trade he's ever made was selling 14,000 units of Keros Therapeutics stock on 12 September 2017 worth over $537,740. On average, Mr trades about 3,336 units every 167 days since 2017. As of 6 April 2022 he still owns at least 1,728 units of Keros Therapeutics stock.

You can see the complete history of Mr Rovaldi stock trades at the bottom of the page.

Mr. Christopher Rovaldi M.Sc. biography

Christopher Rovaldi M.Sc. is the Chief Operating Officer at Keros Therapeutics.

How old is Mr Sc?

Mr Sc is 47, he's been the Chief Operating Officer of Keros Therapeutics since . There are 4 older and no younger executives at Keros Therapeutics. The oldest executive at Keros Therapeutics, Inc. is Dr. Jasbir Seehra Ph.D., 65, who is the Pres, CEO, Treasurer, & Director.

Insiders trading at Keros Therapeutics

Over the last 4 years, insiders at Keros Therapeutics have traded over $50,765,607 worth of Keros Therapeutics stock and bought 2,504,088 units worth $46,191,339 . The most active insiders traders include Ran Nussbaum, Carl L Gordon, and Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $3,312,649. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth $11,002,500.

What does Keros Therapeutics do?

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Complete history of Mr Rovaldi stock trades at Acceleron Pharma Inc and Keros Therapeutics

Keros Therapeutics executives and stock owners

Keros Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Jasbir Seehra Ph.D.,
  Pres, CEO, Treasurer, & Director
• Dr. Jennifer Lachey Ph.D.,
  Chief Scientific Officer
• Keith C. Regnante,
  Chief Financial Officer
• Christopher Rovaldi M.Sc.,
  Chief Operating Officer
• Dr. Simon Cooper MBBS,
  Chief Medical Officer
• Robin Wagner,
  VP of HR
• Esther Cho J.D.,
  Head of Legal & Corp. Sec.
• Julius Knowles,
  
• Tomer Kariv,
  
• Carl L Gordon,
  Director
• Ran Nussbaum,
  
• Nima Farzan,
  
• Tomer Pontifax (Israel) Iv,...,
  
• Mary Ann Gray,
  
• Ran Pontifax (Israel) Iv, L...,
  
• Alpna Seth,
  
• Keith Regnante,
  CHIEF FINANCIAL OFFICER
• Jasbir Seehra,
  CHIEF EXECUTIVE OFFICER
• Christopher Rovaldi,
  CHIEF OPERATING OFFICER
• Jennifer Lachey,
  Chief Scientific Officer
• Claudia Ordonez,
  Chief Medical Officer
• Alon Lazarus,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Management 4 G.P. (2015) Lt...,
  
• Bio Ventures Limited Partne...,
  
• Simon Peter Cooper,
  CHIEF MEDICAL OFFICER
• Jean Jacques Bienaime,